Two studies were cited mainly for increasing the interval. In a Lancet study published earlier this year, efficacy result in phase-3 clinical trial of two doses of OxfordAstraZeneca (Covishield equivalent) was 55.1% when the second dose was given in less than six weeks. This reuslt was from a combined analysis of the participants from the UK, Brazil and South Africa. They indicated that the efficacy was 81.3% when the dosing interval stretched to 12 weeks or more. But supply shortage also played a part in India? United States in March 2021, showing vaccine efficacy of 76% against symptomatic Covid-19 when the interval between doses was four weeks. Even now, India's vaccination effort is slow. After many months of coverage of the eldery (above 60 years), little over 22% are covered with either one dose or two doses. The Delta variant. Public Dealth Engalnd studies showed two doses of Oxford-AstraZeneca given at an eight-week interval are 92% effective against hospitalisation for the Delta variant. Now, UK data, which includes effects of a rapid vaccination programme, offers evidence that the second dose should be given quicker to get better protection against death and prevent hospitalisation. After Bombay HC in the Sushant Singh Rajput case and Delhi HC in northeast Delhi riots cases, it is Karnataka HC's turn to question selective media leaks by police. It's true that official investigators often use media leaks to try and defame accused persons, and sometimes even victims. But the solution is not to muzzle the media. Some advocate using the Contempt of Courts Act, which has provisions forbidding publication that hinders "administration of justice". It's for good reason that these provisions are rarely used. Application of these rules will rapidly shrink medai freedom, which is under other threats anyway.
